Approval · Notice of Compliance 29631 · 2022
TALTZ: Notice of Compliance 29631
Issued September 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29631
- Date
- September 21, 2022
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in formulation
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TALTZ | Not yet assigned | — |
Medicinal ingredients
- IXEKIZUMAB 80 MG per ML
- IXEKIZUMAB 80 MG per PEN